ArticleJournal for immunotherapy of cancer2023

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).

Sophie Postel-Vinay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.